Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

RECOVERY, 2022 NCT04381936

baricitinib (n=4148) vs. standard of care (n=4008)

randomized controlled trial   some concerns about risk of bias

Studied treatment

baricitinib 4 mg once daily
baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner

Control treatment

usual standard of care alone

Patients

COVID 19 all comers

Method

open-label

Remark